Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can light therapy loosen tight skin? new trial aims to find out

NCT ID NCT04922736

Symptom relief Sponsor: University of Utah Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether 30 sessions of UVA-1 light therapy can improve daily life for people with scleroderma, morphea, or skin hardening from graft-versus-host disease. Thirty adults will report how their symptoms affect everyday tasks before and after treatment. The goal is to see if patient-reported outcomes can capture real-world benefits that standard measures might miss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
UVA-1 phototherapy (light treatment)
What this could lead to
If it works, this could show that UVA-1 therapy meaningfully eases skin tightness and improves daily function for people with sclerosing skin diseases.
What could go wrong
This is a small, early study with only 30 people and no comparison group, so results may not apply widely. The treatment requires many sessions and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2021

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Must be able to understand and provide written informed consent * Must have a diagnosis of systemic scleroderma with cutaneous sclerosis, morphea, or sclerodermatous Graft vs. host disease based on the presence of characteristic clinical findings * Age of at least 18-years-old * Ability to engage in 30 UVA-1 treatments in a maximum of 100 days. Exclusion criteria: * Inability to complete study visits * UV light therapy in the 4 weeks prior to entering the study * Commercial tanning in the 4 weeks prior to entering the study * Current pregnancy or planned pregnancy during the study period * History of intolerance to ultraviolet light * Any other condition that will disqualify the patient from the study in the opinion of the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graft VS host disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic graft versus host disease graft versus host disease localized scleroderma systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graft VS host disease Morphea Scleroderma, systemic

Contacts and locations

Locations

  • University of Utah Dermatology

    Murray, Utah, 84132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.